01952 EVEREST MED-B
- 22.050
- -0.850-3.71%
EVEREST MED-B News
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
EVEREST MED-B: (1) GRANT OF OPTIONS (2) GRANT OF AWARDS (3) NON-EXEMPTED CONNECTED TRANSACTIONS - PROPOSED AWARD GRANTS TO CONNECTED PERSONS
EVEREST MED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
EVEREST MED-B: VOLUNTARY ANNOUNCEMENT VOLUNTARY LOCK-UP UNDERTAKING BY CONTROLLING SHAREHOLDER AND CERTAIN SENIOR MANAGEMENT
EVEREST MED-B: DATE OF BOARD MEETING
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
EVEREST MED-B: UPDATE IN RELATION TO DISCLOSEABLE TRANSACTION - (1) COLLABORATION AND LICENSE AGREEMENT; AND (2) SHARE ISSUANCE AGREEMENT IN RESPECT OF THE MANUFACTURE, DEVELOPMENT AND COMMERCIALIZATION OF COVID-19 VACCINES AND CERTAIN LICENSED PRODUCTS
EVEREST MED-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
EVEREST MED-B: CHANGE OF NON-EXECUTIVE DIRECTOR
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
EVEREST MED-B: VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE
EVEREST MED-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
EVEREST MED-B: CHANGE OF NON-EXECUTIVE DIRECTOR
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
EVEREST MED-B: VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE APPROVAL OF NEW DRUG APPLICATION IN CHINA FOR NEFECON FOR THE TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY IN ADULTS AT RISK OF DISEASE PROGRESSION
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
EVEREST MED-B: Next Day Disclosure Return
EVEREST MED-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
EVEREST MED-B: VOLUNTARY ANNOUNCEMENT COLLABORATION AND LICENSE AGREEMENT WITH KEZAR TO DEVELOP AND COMMERCIALIZE ZETOMIPZOMIB IN GREATER CHINA AND OTHER ASIAN MARKETS
Analysis
Price Target
No Data
